A registered PHASE2 study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.
What the source actually supports
- Evidence stage
- Phase 2
- Study design
- RANDOMIZED · PARALLEL · TREATMENT · DOUBLE
- Evidence population
- Human clinical study registration
- Participants
- 136
- Population
- ALL · 50 Years to 90 Years
- Duration
- 2015-03-03 to 2016-10-18
- Intervention
- LHA510 ophthalmic suspension; LHA510 vehicle; Ranibizumab ophthalmic solution
- Comparator
- Vehicle
- Outcomes measured
- Number of Subjects With Positive LUCENTIS® Retreatment Status at Day 84 — Day 84; Time to First LUCENTIS® Retreatment Need Identification up to Day 84 — Day 14, Day 28, Day 56, Day 84; Number of LUCENTIS® Retreatment Needs Identified Required up to Day 84 — Up to Day 84; Number of Subjects Requiring LUCENTIS® Retreatment at Days 28 and 56 — Day 28, Day 56; Change From Randomization Visit (Day -1) in Central Subfield Thickness Total (CSFTtot) at All Visits at the Study Site…; Change From Randomization Visit (Day -1) in Best Corrected Visual Acuity (BCVA) at All Visits at the Study Site — Day -…; Change From Randomization Visit (Day -1) in Central Subfield Thickness, Neuro-retina (CSFTnr) by Visit — Day -1, Day 28…; Change From Randomization Visit (Day -1) in Lesion Thickness by Visit — Day -1, Day 28, Day 84; Change From Randomization Visit (Day -1) in Subretinal Fluid - Foveal Involvement (SRFfi) Thickness by Visit — Day -1,…; Change From Randomization Visit (Day -1) in Pigment Epithelial Detachment - Foveal Involvement (PEDfi) Thickness by Vis…; Change From Randomization Visit (Day -1) in Total Lesion Size by Visit — Day -1, Day 84; Change From Randomization Visit (Day -1) in CNV Size by Visit — Day -1, Day 84; Plasma Concentration of LHA510 and CRA398 — Day 28, Day 84
- Reported result
- No reusable finding-level result is available in this record.
Main limitationThis is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.
Safety and approvalEligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians. Trial registration is not regulatory approval and does not establish that an intervention is available.
Source supportStructured registry protocol metadata; no finding-level conclusion is generated.
Registration and recruitment status do not establish safety, efficacy, or regulatory approval.
Why this record appears here · 100% topic match
The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.
- Vision ageing · 100%Title contains controlled topic terminology. Source terminology contains a controlled topic term. Title supplies ageing or longevity context.
Automated source check 100% · update recency 50%. These figures help sort records; they are not medical ratings.